Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8N9VF
|
|||
| Drug Name |
Ifetroban
|
|||
| Synonyms |
Ifetroban; 143443-90-7; BMS-180291; BMS 180291-02; 3-[2-[[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoic acid; E833KT807K; Benzenepropanoic acid, 2-((3-(4-((pentylamino)carbonyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)-, (1S-(exo,exo))-; Ifetroban [USAN:INN]; UNII-E833KT807K; o-((1S,2R,3S,4R)-3-(4-(Pentylcarbamoyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)hydrocinnamic acid; O-[[1S,2R,3S,4R)-3-[4-(Pentylcarbamoyl)-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]hydrocinnamic acid; BMS180291; BMS 180291; IFETROBAN [INN]; IFETROBAN [USAN]; SCHEMBL28135; GTPL1987; CHEMBL3301673; DTXSID40869931; CHEBI:188730; BDBM50212318; AKOS040748563; DB12321; BMS 180,291; HY-105218; CS-0025381; Q5991162; 3-[2-[[(1S,4R,5S,6R)-5-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-6-yl]methyl]phenyl]propanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Aspirin-induced asthma [ICD-11: CA23.20] | Phase 2 | [1] | |
| Company |
Cumberland Pharmaceuticals Nashville, TN
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H32N2O5
|
|||
| Canonical SMILES |
CCCCCNC(=O)C1=COC(=N1)C2C3CCC(C2CC4=CC=CC=C4CCC(=O)O)O3
|
|||
| InChI |
InChI=1S/C25H32N2O5/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29)/t18-,20-,21+,23-/m0/s1
|
|||
| InChIKey |
BBPRUNPUJIUXSE-DXKRWKNPSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thromboxane A2 receptor (TBXA2R) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Platelet activation | ||||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| Thromboxane signalling through TP receptor | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| Signal amplification | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03326063) Therapeutic Control of Aspirin-Exacerbated Respiratory Disease. U.S.National Institutes of Health. | |||
| REF 2 | Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.